| Names | |
|---|---|
| IUPAC name 1-[(3,4-dihydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol | |
| Other names Norlaudanosoline; Tetrahydroxypapaveroline | |
| Identifiers | |
3D model (JSmol) | |
| 313061 | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.158.898 |
| EC Number |
|
| KEGG | |
| UNII | |
| |
| |
| Properties | |
| C16H17NO4 | |
| Molar mass | 287.315 g·mol−1 |
| Hazards | |
| GHS labelling:[1] | |
| Warning | |
| H302 | |
| P264,P270,P301+P317,P330,P501 | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Tetrahydropapaveroline, also known asnorlaudanosoline, is atetrahydroisoquinolinealkaloid. It is also classified as abenzylisoquinoline alkaloids.[1]
Tetrahydropapaveroline is relevant to brain pathologies.[2]
It can be formed in trace amounts in the brain by acondensation reaction ofdopamine anddopaldehyde (ametabolite of dopamine).[2][3]
It inhibits dopamine uptake within thecerebral cortex.[4]